Search PubMed⌕ Search

Biomedical subjects

G Gadaleta

Publications and source records attributed to G Gadaleta.

At least 37 records · Page 2Linked to original sources
PubMed1981

The nucleotide sequence of the large ribosomal RNA gene and the adjacent tRNA genes from rat mitochondria.

We have sequenced the Eco R(1) fragment D from rat mitochondrial DNA. It contains one third of the tRNA (Val) gene (the remaining part has been sequenced from the 3' end of the Eco R(1) fragment A) the complete gene for the large mt 16S rRNA, the tRNA (Leu) gene and the 5' end of an unidentified reading frame. The mt gene for the large rRNA from rat has been aligned with the homologous genes from mouse and human using graphic computer programs. Hypervariable regions at the center of the molecule and highly conserved regions toward the 3' end have been detected. The mt gene for tRNA Leu is of the conventional type and its primary structure is highly conserved among mammals. The mt gene for tRNA(Val) shows characteristics similar to those of other mt tRNA genes but the degree of homology is lower. Comparative studies confirm that AGA and AGG are read as stop codons in mammalian mitochondria.

Animals↗
PubMed1981

The characterization of the area of rat mitochondrial DNA containing the large ribosomal RNA gene.

The base sequence of the Eco-RI D fragment from rat liver mtDNA, cloned in recombinant plasmid, has been analyzed, This fragment contains the genes for the 16SRNA of the large ribosomal subunit and the tRNA(Leu). Comparisons between these genes and corresponding regions either in other mitochondrial genomes or in E. coli DNA are presented, that allow some interesting evolutionary and phylogenetic considerations.

Animals↗
PubMed1978

[Long-term cardiac pacing: survival above 10 years (author's transl)].

The authors reports data of pacemaker patients surviving above 10 years. They have considered 241 patients undergone pace-maker first insertion from January 1961 to June 1967 (168 treated with epicardial and 73 with transvenous electrodes). At the last control on July 1977, 52 (27 males and 25 females) were surviving, equivalent to 21% of all patients treated in that period. The age of these patients ranged from 5 to 83 (mean 60 years) at first implantation. At present 51 patients are treated with transvenous systems, only 1 patient is stimulated with epicardial pace-maker. 382 pace-makers were used in these 52 patients: the average life of every pacer was 20 months. Complications relative to epicardial and endocardial pacing are reported: with the transvenous system the percent of complications was lower (15,6% to 50,4%). Finally present clinical states of the 52 patients are reported, basing on the reccomendations of Criteria Committee of the New Heart Association.

Adolescent↗
PubMed1978

[Permanent endocardial pacing. Experience on 1678 patients. (De Gasperis Cardiology Center--Ente Ospedaliero Niguarda--Milano) (author's transl)].

The Authors report on eleven years and six months experience with permanent endocardial pacing in the treatment of various conduction disturbances. This experience relates to 1678 patients, 3617 pacers were used. The age of the patients ranges from 60 to 80 (70%), 30% referring to the remaining decades, minimum 14--maximum 94. Fixed rate pacers were used in 31% of cases, QRS synchronous or QRS inhibited pacers were used in 69%. Average life of the pacers varies from 25 to 29 months; the average life of fixed rate pacer is higher. Complications and causes of failures, among which electrode dislodgement is the most relevant and frequent, as well as the relative therapeutical treatments, are described. Early mortality is about 1% and late mortality 20%; the survival rate calculated altogether after 11 years and 6 months treatment with implantable pervenous pacing is about 16%.

Aged↗
PubMed1978

[The Italian experience with lithium pacemaker (author's transl)].

After explaining the concept and evolution of lithium-anode batteries, and the various types in use at present as power sources for pulse generators, the Authors examine the Italian studies, including pacemaker's clinical follow-up, technical trials and productions. In fact the first pulse-generators, powered by the best known battery prototypes, i.e. old Lithium-Iodine cell 702 C,P, and E, and Lithium-Silver Chromate cell Li 210 and Li 355, were implanted respectively in 1972, 1973 and 1974, at the Cardiology Department, Ferrara, Italy. The detailed account and analysis of the data supplied by both Italian and Foreign manufacturers, together with the observations furnished by 24 Pacing-Centres--2845 pacemakers implanted for a total amount of 31,794 months/pacemaker out of 8,475 pacemakers supplied for 77,606 months/pacemaker up to June, 30, 1977-indicate a promising future for the development of such pulse-generators. Indeed the latest improved power sources associated with the best and most reliable electronic and electrode pacing systems, already allow the manufactures to produce small, comfortable and long-term pacemakers. Furthermore the significant reduction in periodic controls and replacements, if actually needed, seems sufficient in itself to counterbalance the initial high cost. Thus, medical staff and equipment can be utilized for other purposes.

Electric Power Supplies↗
PubMed1978

[The Italian experience in permanent pacing. A casuistry for more of 10 years: a policentric study (author's transl)].

According to a recent national survey, 387 patients were treated by permanent pacing in 10 Italian centers, between 1961 and 1966. Of these patients 205 have died; 131 (77 males and 54 females) are still alive and no informations could be obtained for the remaining 51 (13%). The overall survival of patients treated during this period of time is therefore not less than 34% which is comparable to that of general population of the same age group. The 131 patients still alive have totaled 1,486 years of pacing and have used up to 784 pacers. Comparing the incidence of the most common causes for replacement during the periods 1961-66 and 1973-77, electrode failures dropped from 21 to 0.9%; circuitry malfunctions occurred in 10.5 and 7.8%; battery depletion rose from 36.8 to 69% of the cases. According to their clinical conditions, the 131 patients on long-term follow-up can be grouped as follows: 62% are in class 1 or 2 of NYHA; 26.7% are in class 3, and 3.8% in class 4. Moreover, 53.4% of patients are living an active life, having some sort of occupation and 29% are holding a driving license.

Aged↗
PubMed1978

[Cardiac pacing as prophylaxis in surgical operations (author's transl)].

During a 24-month period, 37 patients with fascicular blocks (RBB-LAH, alternating bundle-branch block, bundle-branch block with PR prolongation, RBBB-LAH with PR prolongation) were sheduled for operation. The study was undertaken to determine what effect the stress of anesthesia and operation might have on these patients, and to attempt to answer the question whether all patients with fascicular block should have demand pacemakers implanted. All these patients were in stable condition and had no history of transient complete heart block. Patients were monitored continuously intraoperatively and were followed by serial electrocardiograms to the third postoperative day. No instance of complete heart block was found. No significant problem arose both intra- and postoperatively. According to these findings, routine, prophylactic, temporary cardiac pacing in patients with fascicular blocks, before anesthesia and during operation, seems to be not necessary in the absence of cardiac symptoms.

Aged↗
PubMed1976

[Permanent endocardiac electric stimulation. Observations on 1125 patients (1 January 1966-31 August 1974)].

The authors report on nine years' experience with permanent endocardial pacing in the treatment of various conduction disturbances. Their experiences relate to 1125 patients; 2208 pacers were used. The age of the patients ranges from 60 to 80 (85%), 15% referring to the left decades, minimum 17 - maximum 94. Fixed rate pacers were used in 41% of cases, QRS synchronous or QRS inhibited pacers were used in 59%. Average life of pacers varies from 8.5 to 28.3 months; the average life of fixed rate pacers is higher. Complications and causes of failures, among which electrode dislodgement is the most relevant and frequent, as well as the relative therapeutical treatments, are described. Early mortality is about 1% and late mortality 8-9%: the survival rate calculated altogether after 9 years' treatment with implantable pervenous pacing is about 24%.

Adolescent↗